LYNN LINEBERRY: Open Payments
NPI 1073142683 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 60 payments from 13 companies in 2025. Trend: 2023 $966 · 2024 $586 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $158 |
| Amgen Inc. | 23 | $145 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 7 | $90 |
| Alnylam Pharmaceuticals Inc. | 5 | $77 |
| Kestra Medical Technology Services, Inc. | 3 | $75 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Medtronic, Inc. | 3 | $45 |
| Merck Sharp & Dohme LLC | 3 | $43 |
| Novo Nordisk Inc | 1 | $26 |
| Edwards Lifesciences Corporation | 1 | $22 |
Products named: REPATHA, LEQVIO, LifeVest, AMVUTTRA, Assure WCD, FARXIGA, LINQ II, VERQUVO.
Industry payments across AR — which companies pay providers there.
